Articles by Ruey-ching (Richard) Hwang, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Ruey-ching (Richard) Hwang, PhD

Ruey-ching (Richard) Hwang, PhD

research manager

Ruey-ching (Richard) Hwang, PhD, is a senior director of pharmaceutical sciences at Pfizer and a member of Pharmaceutical Technologys editorial advisory board.

Articles
Preformulation in Theory and Practice
June 2, 2008

An ambitious survey of characterization techniques presents current information.

Trends and Innovations in Continuous Coating
January 25, 2008

The technique of continuous coating has undergone great change since it was introduced to the pharmaceutical industry more than a decade ago, and its benefits have multiplied.

Design of Experiments for Formulation Development
December 1, 2005

All pharmaceutical products are formulated to specific dosage forms for drugs to be effectively delivered to patients. Typical pharmaceutical dosage forms include oral tablets, capsules, solutions, suspensions, topical ointments, gels, and solutions, and injections for intravenous (IV), intramuscular (IM), or subcutaneous (SC) administration. In addition, various drug delivery systems have been developed for transdermal, intranasal, and pulmonary deliveries. Different dosage forms require different pharmaceutical technologies and usually present different technical challenges for formulation development.

A Systematic Evaluation of the Compression and Tablet Characteristics of Various Types of Lactose and Dibasic Calcium Phosphate
June 2, 2001

Using formulations containing various types of lactose and dibasic calcium phosphate, the authors investigated the effects of lubricant level, lubrication time, and compression speed on tablet weight, hardness, and friability.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here